Objective: To explore the correlation between the anti-β2 glycoprotein I antibody (anti-β2 GPI) and acute coronary syndrome (ACS). Methods: Serum levels of anti-β2 GPI antibody were detected in 168 patients with acute coronary syndrome (ACS) by the method of ELISA. Coronary angiography (CAG) were taken and the implicated vessels were remodeled. Patients were divided into high, middle and low anti-β2 GPI antibody level group according to the results of ELISA. The correlation between the anti-β2 GPI antibody and the clinical classification [ ST segment elevation myocardial infarction ( STEMI) , non-ST segment elevation myocardial infarction ( NSTEMI) , unstable angina ( UA) ] were assessed. All of patients were followed up for 12 months, and the correlation between anti-β2 GPI antibody and the severity of the disease and the main adverse cardiac events (MACEs) were evaluated in patients with ACS. Results; Serum levels of anti-β2 GPI antibody in patients with STEMI、NSTEMI and UA were (63. 4 ±32. 6) RU/ml, (39. 8 ±25. 9) RU/ml, (22. 1 ± 10.4) RU/ml respectively, and the level was higher in patients with STEMI, and lowest in patients with UA. In the high level group of anti-β2 GPI, STEMI accounted for 90. 9% (10/11 ) , higher than that of the middle (29/96) and low (1/61) groups ( P <0. 01) . All of the patients were followed up for 12 months, and the follow-up rate was 98% . Four patients in high level groups had MACEs, the incidence was 36. 4% which was higher than that of the middle (4. 2% ) and low level (3.5% ) groups. Logistic regression analysis of multiple factors indicates that high level of anti-β2 GPI antibody was one of the independent risk factors of developing MACEs in ACS patients. Conclusions: Anti-β2 GPI is associated with the severity of the ACS and MACEs. High level of anti-β2 GPI antibody was one of the independent risk factors of recurring MACEs in ACS.%目的:探讨抗β2糖蛋白Ⅰ型抗体(抗β2GPI抗体)与急性冠脉综合征(ACS)的临床相关性.方法:采用酶联免疫吸附法检测168例ACS患者血清中抗β2GPI抗体的浓度水平,同时进行冠脉造影术检查,并对罪犯血管进行血管重建.根据抗体浓度水平分为高、中、低浓度组,分析各组中抗体浓度与ACS临床分型[急性ST段抬高型心肌梗死(STEMI)、急性非ST段抬高型心肌梗死(NSTEMI)、中危以上不稳定型心绞痛(UA)]的相关性,随访12个月,评价抗β2 GPI抗体浓度与ACS患者的疾病严重程度及主要不良心血管事件(MACEs)的相关性.结果:ACS中STEMI、NSTEMI、UA患者抗β2GPI抗体浓度依次是(63.4±32.6) RU/ml,(39.8±25.9) RU/ml,(22.1±10.4)RU/ml,其中STEMI患者抗体浓度较高,UA患者的抗体浓度最低.抗β2GPI抗体的高浓度组中STEMI( 10/11)占90.9％,高于中浓度组(29/96)和低浓度组(1/61) (P ＜0.01).随访观察12个月,随访率98％；抗β2GPI抗体高浓度组有4例发生MACEs,发生率36.4％,显著高于中浓度组(4.2％)和低浓度组(3.5％).多因素回归分析提示抗β2 GPI抗体高浓度是预测ACS发生MACEs的独立危险因素之一.结论:抗β2GPI抗体浓度与ACS患者疾病的严重程度及MACEs密切相关,抗β2GPI抗体高浓度是ACS再发MACEs的独立危险因素之一.
展开▼
